Overview section

Diane-35 is a combined oral formulation that pairs a synthetic estrogen with a progestin that has antiandrogen activity. Outside the United States it is commonly used both as a contraceptive and to treat androgen-related skin and hair problems such as acne and excess hair growth. This specific product is not approved for marketing in the United States. For information about availability and import rules, see the US the rule of law and public access notes.

• Drug class: combination estrogen with antiandrogenic progestin.
• Common international suggestions: contraception, management of acne, and treatment of hirsutism.
• U.S. status: not approved by the U.S. Food and Drug Administration for sale.

Concise facts

• Typical composition: cyproterone acetate 2 mg with ethinyl estradiol 0.035 mg.
• Main intended effects: reduce androgen-driven acne and hirsutism while preventing pregnancy.
• If you are in the United States, consider FDA-approved options listed under Choice other possibilities available in the United States.

Pharmacologically active constituents found in this product with strength details

A commonly used Diane-35 tablet contains:

• Cyproterone acetate 2 mg — an antiandrogenic progestin.
• Ethinyl estradiol 0.035 mg (35 micrograms) — a synthetic estrogen.

These amounts are often expressed as 2 mg cyproterone acetate with 0.035 mg ethinyl estradiol per active tablet.

Red flags and intended uses

In healthcare systems where Diane-35 is prescribed, clinicians commonly choose it for patients who need reliable contraception and who also have acne or hirsutism thought to be driven by androgen excess. Typical reasons for selection include:

• Moderate to severe acne with a suspected hormonal component.
• Hirsutism causing unwanted facial or body hair.
• Contraception combined with menstrual regulation.

In advance of starting hormonal therapyverification the precautions to take and the health risks that preclude therapy to ensure it is an appropriate choice.

Another set of options available in the United States

Because Diane-35 is not available in the U.S., clinicians typically prescribe FDA-approved contraceptives or other therapies to manage acne and excess hair. The selection depends on treatment priorities, safety profile, and reproductive plans.

• Combined oral contraceptives with lower androgenic potential:
  • Ethinyl estradiol with drospirenone (examples: Yaz, Yasmin and generics) — often favored for acne benefit in some patients.
  • Ethinyl estradiol with norgestimate (examples: Ortho Tri-Cyclen and generics) — an FDA-approved option for acne and contraception.
• Progestin-only methods:
  • Opill (norgestrel 0.075 mg) — available over the counter as a daily progestin-only pill; it is not indicated for acne treatment.
  • Long-acting reversible contraception such as levonorgestrel IUDs or implants — effective for pregnancy prevention but may not improve acne and could worsen it in some people.
• Systemic agents used off-label or adjunctively:
  • Spironolactone — commonly prescribed off-label for acne and hirsutism; must be combined with reliable contraception when pregnancy is possible.
  • Metformin — can be helpful when polycystic ovary syndrome (PCOS) or insulin resistance is present, addressing metabolic features and menstrual irregularity.
• Topical dermatologic treatments:
  • Clascoterone 1% cream — a topical antiandrogen approved in the U.S. for acne.
  • Topical retinoids, benzoyl peroxide, and combination formulations — mainstays of acne therapy.

When selecting an a further option, discuss clotting history, migraines, blood pressure, smoking status, and family history of hormone-sensitive cancers with your provider.

How it is taken (typical regimen where used)

Adhere to the instructions provided by your prescriber. Where Diane-35 is used, a common regimen is one active tablet daily for 21 days followed by a 7-day tablet-free interval. Providers may advise different schedules based on clinical objectives.

Switching from another hormonal product or starting treatment for dermatologic reasons often requires specific start-up guidance and sometimes a short period of backup contraception. See advice on skipping a dose for advice if tablets are missed.

Safety guidelines for safe operation considerations

Important safety topics to review with a clinician include:

• Pregnancy and lactation: combined hormonal contraceptives are not recommended during pregnancy and generally are avoided while breastfeeding.
• Liver disease: significant hepatic impairment or liver tumors usually preclude use of estrogen-containing medicines.
• Blood clot risk: estrogen-containing products increase the risk of venous and arterial thromboembolism; a careful personal and family history of clotting is essential.
• Smoking and age: tobacco use in people over age 35 markedly raises cardiovascular risk with estrogen therapy.
• Obesity and metabolic conditions: these can increase cardiovascular risk and influence product selection.

For a detailed list of exclusions, consult the situations in which therapy is not appropriate and exclusions the current section.

Where use is contraindicated and who should abstain from taking it?

The following situations typically exclude patients from receiving Diane-35 or similar combined hormonal medicines:

• Known or suspected pregnancy, or current breastfeeding.
• History of deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction.
• Hepatic disease in an active or severe form, or known hepatic tumors.
• Current or past hormone-sensitive cancers, such as breast cancer.
• Migraine i am suffering from a headaches with aura or severe recurrent migraines.
• Uncontrolled hypertension or diabetes with vascular complications.

Patients with multiple cardiovascular risk factors should consult a specialist to determine safe other options.

Potential adverse outcomes

Unwanted effects reported with combined estrogen-progestin products can include:

• Nausea, abdominal discomfort, or vomiting.
• The pain in the head and attainable worsening of migraine.
• Fluctuating breast tenderness or breast changes.
• Weight fluctuation or fluid retention.
• Mood changes and emotional variability.
• Breakthrough bleeding or spotting, especially during the first months of use.

If you experience sudden symptoms suggestive of a blood clot (for example, sudden shortness of breath, chest pain, unilateral leg swelling, sudden severe head ache, or visual change), obtain emergency medical care immediately. If you think you or a child has taken too much medication, see background information on consuming an overdose.

Medicinal product social interactions span conversations, gestures, and feedback.

Certain drugs and supplements can reduce hormonal effectiveness or alter safety. Tell your clinician about all medicines and supplements you take, particularly:

• Enzyme-inducing anticonvulsants such as phenytoin, carbamazepine, and topiramate.
• Certain antiretroviral therapies, for example regimens that include ritonavir.
• Rifampin and related antibiotics that increase hepatic metabolism.
• Herbal products like St. John s wort that may lower hormone levels.
• Anticoagulant drugs — real time intercommunications enable quick problem solving. can affect bleeding risk and observation and tracking.

If a concomitant medication is likely to reduce hormone concentrations, your prescriber may advise extra contraceptive safety precautions or an an additional choice regimen. Gaze at the protocol for a one dose was missed for further steps when the act of connecting with otherss with others are the core of collaboration. are present.

Dose omission management guidance

• If you remember shortly after missing a tablet, take the missed pill as soon as you recall.
• If the next dose is due soon, skip the missed tablet and continue the schedule; do not double up without medical advice.
• If several consecutive tablets are missed, use backup contraception and contact your clinician for specific instructions.

Different products and regimens may have tailored recommendations; always follow the instructions provided by your prescriber or pharmacist.

Overdosing episode information sheet

Ingesting more than the prescribed amount may cause increased nausea, vomiting, dizziness, abdominal pain, or cranial pain. In children, excessive ingestion can lead to drowsiness. If an experiencing an overdose is suspected, contact your healthcare provider, your local poison control center, or emergency services right away for evaluation and informed direction.

Ways to keep items safely

• Keep tablets in a cool, dry place away from direct sunlight.
• Maintain cold storage is used for long term preservation of rare items. below 25 C (77 F) where possible and avoid excessive heat and humidity.
• Store all medication out of reach of children and household pets.

Estimated prices in the United States (USD)

Diane-35 itself is not marketed in the United States, so no domestic retail price applies. Below are approximate monthly out-of-pocket ranges for common complementary and integrative therapies. Actual costs depend on pharmacy, insurance, available generics, and discount programs.

• Generic combined oral contraceptives (various formulations): about 10 to 50 USD per month.
• Drospirenone-containing products (Yaz, Yasmin, generics): roughly 15 to 200 USD per month depending on brand and coverage.
• Norgestimate-containing options (Ortho Tri-Cyclen, generics): commonly 10 to 60 USD per month.
• Opill (OTC norgestrel 0.075 mg): usually 19 to 50 USD per month.
• Spironolactone (generic) for acne/hirsutism: roughly 4 to 15 USD per month for common therapeutic dose.
• Generic metformin costs in the 4 to 10 USD per month range.
• Topical retinoid generics: around 10 to 50 USD; branded formulations can cost more.
• Topical clascoterone 1% cream: often several hundred USD per month before insurance or discounts.

Store-to-store price comparison tip: generic versions and manufacturer coupons usually cost less than branded products. Pharmacy price checking, mail-order services, and patient assistance programs can reduce out-of-pocket expenses.

American legal structure and access briefs

• FDA approval: Diane-35 (cyproterone acetate plus ethinyl estradiol) is not approved by the FDA alongside therefore is not legally marketed in the United States.
• Importation: Importing unapproved prescription medicines is generally not permitted. The FDA may exercise enforcement discretion in very limited circumstances, but shipments of unapproved products can be detained or refused.
• Prescription access in the U.S.: Most hormonal contraceptives require a prescription; some states permit pharmacists to furnish or initiate specific contraceptives after screening.
• Over-the-counter options: Emergency contraception containing levonorgestrel in conjunction with the daily progestin pill Opill are available without a prescription in the U.S.
• Telehealth: Many clinicians provide contraception, acne, and hirsutism therapies via telehealth where allowed by state law and clinical judgment.

For safety and compliance, obtain medicines that are approved for use in the United States through licensed prescribers and pharmacies rather than attempting to source unapproved products. For different choices that address similar clinical needs, see Alternate options available in the United States.

Clinical notes and daily reminders

• Follow the exact regimen and time sensitive monitoring plan recommended by your healthcare professional.
• If you develop sudden severe symptoms such as chest pain, trouble breathing, leg swelling, or neurologic changes, seek emergency care without delay.
• Store and handle medicines as described in the practical seasonal storage spaces provide room for off-season items. advice this section.

This page is intended as a general a compact overview of the section and does not replace individualized medical advice. For diagnosis, treatment, or medication decisions consult a qualified healthcare provider.